Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2666-2672
doi: 10.1161/hc4701.099787
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Undas, A.
Right arrow Articles by Szczeklik, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Undas, A.
Right arrow Articles by Szczeklik, A.
Related Collections
Right arrow Coagulation
Right arrow Thrombin
Right arrow Platelet function inhibitors
Right arrow Gene expression

(Circulation. 2001;104:2666.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

PlA2 Polymorphism of ß3 Integrins Is Associated With Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury

Anetta Undas, MD, PhD; Kathleen Brummel, PhD; Jacek Musial, MD, PhD; Kenneth G. Mann, PhD; Andrew Szczeklik, MD, PhD

From the Department of Medicine, Jagellonian University School of Medicine, Krakow, Poland, and the Department of Biochemistry, University of Vermont, Burlington, Vt (K.B., K.G.M.).

Correspondence to Dr Kenneth G. Mann, University of Vermont, Department of Biochemistry, Given Building, Room E407, Burlington, VT 05405. E-mail kmann{at}protein.uvm.edu

Background— Mechanisms by which the PlA2 (Leu33Pro) polymorphism of ß3 integrins could lead to an increased risk for coronary events are unclear. This study was designed to examine the effect of this polymorphism on blood coagulation.

Methods and Results— In normal subjects (12 with PlA1A1, 9 with PlA1A2, and 3 with PlA2A2), we evaluated the activation of prothrombin, factor V, and factor XIII and fibrinogen removal by quantitative immunoblotting; thrombin-antithrombin III complex generation using ELISA; and levels of fibrinopeptide A and B by high-performance liquid chromatography in blood collected every 30 seconds at sites of standardized microvascular injury before and after 7 days of aspirin ingestion (75 mg/d). Compared with the PlA1A1 subjects, the PlA2 carriers exhibited higher maximum rates of thrombin B-chain generation (by 31.6%; P=0.005), thrombin-antithrombin III complex generation (by 30.7%; P=0.003), fibrinogen consumption (by 31.3%; P=0.002), prothrombin consumption (by 26.1%; P=0.011), and activation of factor V (by 14.1%; P=0.033) and factor XIII (by 27.0%; P=0.012). In the PlA1A1 homozygotes, aspirin ingestion resulted in reductions in the velocity of thrombin B-chain formation (by 32.1%; P=0.007), prothrombin consumption (by 30.4%; P=0.018), factor Va generation (by 28.9%; P=0.014), fibrinogen removal (by 41.2%; P=0.001), and factor XIII activation (by 22.6%; P=0.026). In the PlA2 carriers, aspirin did not alter the velocity of all these processes. After aspirin ingestion, fibrinopeptide A and B concentrations in the last 30-second interval were significantly reduced, but only in the PlA1A1 subjects.

Conclusions— The presence of the PlA2 allele is associated with enhanced thrombin formation and an impaired antithrombotic action of aspirin, which might favor coronary thrombosis in the PlA2 carriers.


Key Words: glycoproteins • genetics • coagulation • thrombin • aspirin




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Z. Li, M. A. Nardi, J. Wu, R. Pan, W. Zhang, and S. Karpatkin
Platelet Fragmentation Requires a Specific Structural Conformation of Human Monoclonal Antibody against {beta}3 Integrin
J. Biol. Chem., February 8, 2008; 283(6): 3224 - 3230.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
S. Prabhakaran, K.R Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes
Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting
AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 281 - 285.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A. Jakubowska, J. Gronwald, J. Menkiszak, B. Gorski, T. Huzarski, T. Byrski, L. Edler, J. Lubinski, R. J Scott, and U. Hamann
Integrin {beta}3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk
J. Med. Genet., June 1, 2007; 44(6): 408 - 411.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. Lim, S. Carballo, J. Cornelissen, Z. A. Ali, R. Grignani, S. Bellm, and S. Large
Dose-Related Efficacy of Aspirin After Coronary Surgery in Patients With PlA2 Polymorphism (NCT00262275)
Ann. Thorac. Surg., January 1, 2007; 83(1): 134 - 138.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
S. T. Morozowich, B. S. Donahue, and I. J. Welsby
Genetics of coagulation: considerations for cardiac surgery.
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 297 - 313.
[Abstract] [PDF]


Home page
Exp. Biol. Med.Home page
K. V. Vijayan and P. F. Bray
Molecular Mechanisms of Prothrombotic Risk Due to Genetic Variations in Platelet Genes: Enhanced Outside-In Signaling Through the Pro33 Variant of Integrin {beta}3.
Experimental Biology and Medicine, May 1, 2006; 231(5): 505 - 513.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. H. Wang, D. L. Bhatt, and E. J. Topol
Aspirin and clopidogrel resistance: an emerging clinical entity
Eur. Heart J., March 2, 2006; 27(6): 647 - 654.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. J. Mason, A. K. Jacobs, and J. E. Freedman
Aspirin Resistance and Atherothrombotic Disease
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 986 - 993.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. A. Weiss, L. A. Lester, J. E. Gern, R. L. Wolf, R. Parry, R. F. Lemanske, J. Solway, and C. Ober
Variation in ITGB3 Is Associated with Asthma and Sensitization to Mold Allergen in Four Populations
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 67 - 73.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
J. Mikkelsson, M. Perola, and P. J. Karhunen
Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications
Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125.
[Abstract] [PDF]


Home page
ASH Education BookHome page
C. N. Harrison
Platelets and Thrombosis in Myeloproliferative Diseases
Hematology, January 1, 2005; 2005(1): 409 - 415.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-P. Xiong, T. Stehle, S. L. Goodman, and M. A. Arnaout
A Novel Adaptation of the Integrin PSI Domain Revealed from Its Crystal Structure
J. Biol. Chem., September 24, 2004; 279(39): 40252 - 40254.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Slowik, T. Dziedzic, W. Turaj, J. Pera, L. Glodzik-Sobanska, P. Szermer, M. T. Malecki, D. A. Figlewicz, and A. Szczudlik
A2 Alelle of GpIIIa Gene Is a Risk Factor for Stroke Caused by Large-Vessel Disease in Males
Stroke, July 1, 2004; 35(7): 1589 - 1593.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. L. Bhatt
Aspirin resistance: more than just a laboratory curiosity
J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1127 - 1129.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. V. Potapov, S. Ignatenko, B. A. Nasseri, M. Loebe, C. Harke, M. Bettmann, A. Doller, V. Regitz-Zagrosek, and R. Hetzer
Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support
Ann. Thorac. Surg., March 1, 2004; 77(3): 869 - 874.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
J Natl Cancer Inst, August 6, 2003; 95(15): 1150 - 1157.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Undas, W. J. Sydor, K. Brummel, J. Musial, K. G. Mann, and A. Szczeklik
Aspirin Alters the Cardioprotective Effects of the Factor XIII Val34Leu Polymorphism
Circulation, January 7, 2003; 107(1): 17 - 20.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. G. Mann, S. Butenas, and K. Brummel
The Dynamics of Thrombin Formation
Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. G. Mann and M. Kalafatis
Factor V: a combination of Dr Jekyll and Mr Hyde
Blood, January 1, 2003; 101(1): 20 - 30.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Sajid, K. V. Vijayan, S. Souza, and P. F. Bray
PlA Polymorphism of Integrin {beta}3 Differentially Modulates Cellular Migration on Extracellular Matrix Proteins
Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1984 - 1989.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Pontiggia, R. Lassila, S. Pederiva, H.-R. Schmid, M. Burger, and J. H. Beer
Increased Platelet-Collagen Interaction Associated With Double Homozygosity for Receptor Polymorphisms of Platelet GPIa and GPIIIa
Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2093 - 2098.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Szczeklik, J. Musial, A. Undas, J. W. Eikelboom, J. Hirsh, J. I. Weitz, M. Johnston, Q. Yi, and S. Yusuf
Reasons for Resistance to Aspirin in Cardiovascular Disease * Response
Circulation, November 26, 2002; 106 (22): e181 - e182.
[Full Text] [PDF]